Curated Wealth Partners LLC Has $1.77 Million Position in Abbott Laboratories (NYSE:ABT)

Curated Wealth Partners LLC lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 13.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 15,609 shares of the healthcare product maker’s stock after acquiring an additional 1,889 shares during the period. Abbott Laboratories makes up about 0.2% of Curated Wealth Partners LLC’s investment portfolio, making the stock its 28th biggest position. Curated Wealth Partners LLC’s holdings in Abbott Laboratories were worth $1,766,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in ABT. Future Financial Wealth Managment LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth about $31,000. Peterson Financial Group Inc. acquired a new stake in shares of Abbott Laboratories during the third quarter worth approximately $32,000. Valued Wealth Advisors LLC raised its stake in shares of Abbott Laboratories by 78.4% in the third quarter. Valued Wealth Advisors LLC now owns 289 shares of the healthcare product maker’s stock valued at $33,000 after acquiring an additional 127 shares during the last quarter. Highline Wealth Partners LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $37,000. Finally, JDM Financial Group LLC grew its position in Abbott Laboratories by 51.3% during the 3rd quarter. JDM Financial Group LLC now owns 363 shares of the healthcare product maker’s stock worth $41,000 after acquiring an additional 123 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 1.5 %

Shares of NYSE:ABT opened at $125.12 on Friday. The company has a 50 day moving average price of $115.07 and a two-hundred day moving average price of $113.15. The company has a market capitalization of $217.01 billion, a PE ratio of 16.36, a PEG ratio of 2.51 and a beta of 0.73. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $125.67. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting the consensus estimate of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.97 billion for the quarter, compared to analyst estimates of $11,029,400 billion. During the same period in the previous year, the company posted $1.19 earnings per share. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. Analysts forecast that Abbott Laboratories will post 5.15 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a yield of 1.89%. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 30.85%.

Analysts Set New Price Targets

Several brokerages have recently commented on ABT. Barclays increased their target price on Abbott Laboratories from $143.00 to $149.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. UBS Group increased their price target on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a “buy” rating in a research note on Thursday. Raymond James restated a “buy” rating and issued a $129.00 price objective (up previously from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Stifel Nicolaus lifted their target price on Abbott Laboratories from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Piper Sandler upped their price target on Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.50.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.